Acadia Healthcare Co, Inc is a behavioral healthcare services provider that operates in the United States (U.S) and the United Kingdom (U.K). The company offers acute inpatient psychiatric facilities, specialty treatment facilities, residential treatment centers, and outpatient community-based services. Acadia Healthcare has been in the news with its latest opening at $69.18 on May 8, 2023.
The stock of Acadia Healthcare has a fifty-day simple moving average of $72.03 and a 200-day simple moving average of $78.91. The market cap of Acadia Healthcare is $6.37 billion with a P/E ratio of 22.68. The P/E/G ratio for this company is measured at 1.50, which indicates that it may be overvalued compared to its peers. Additionally, academia healthcare has Beta of 1.31 which shows that it is more volatile than the broader market.
The quick ratio for Acadia Healthcare is measured at 1.42 and the current ratio is also the same indicating that the company’s liquidity position remains favorable with strong cash balance levels present if needed for any unforeseen events.
According to Bloomberg research analysts who have recently issued reports about Acadia Healthcare think positively about this stock due to its potential earnings growth rate potential for future investors who get involved in these shares right now.
In contrast to positive analyst recommendations on ACHC’s earnings growth prospects, following the release on February 27th where ACHC’s net margin was only ten point thirty-two percent with disappointing return on equity numbers at ten point twenty-two percent; a result which has led to analysts downgrading their outlooks concerning ACHC anyway.
Recently Cantor Fitzgerald initiated coverage of Acadia Healthcare Co., recommending purchasing shares but noting that analysis believes that despite opportunities present within this market sector given what appears from an investor perspective as being appropriate valuations currently being charged against academia healthcare stock, this analysis thinks that the company’s shares are not likely to increase significantly resulting in a lack of enthusiasm towards purchasing these shares.
On the other hand, Credit Suisse Group strongly endorses the potential for significant earnings growth on ACHC’s reasonably priced shares and issue noteworthy price predictions of $95.00 for future investors who wish to buy these stocks.
With ACHC’s mission statement in mind – providing quality behavioral healthcare to each patient based on individual needs, as evidenced by this report; whilst the experts disagree; this is one for those investors who want to take a calculated risk.
Mixed Sentiments: Acadia Healthcare’s Earnings Estimate Decreased for Q2 2023, While Hedge Funds Show Confidence
Acadia Healthcare Company, Inc. (NASDAQ:ACHC) encountered a decrease in their Q2 2023 earnings estimates as per the research note issued to investors on Friday, May 5th by Zacks Research. The company’s prior forecast of $0.85 per share has now reduced to $0.76 per share for the quarter ended in June 2023. Despite this dip, Acadia Healthcare’s current consensus estimate for annual earnings stands at $3.26 per share.
Notably, several hedge funds have bought and sold shares of ACHC lately. Altshuler Shaham Ltd and Point72 Hong Kong Ltd are among the ones that acquired a new stake in Acadia Healthcare during the third and first quarters of 2023 respectively, totaling up to an investment worth approximately $64,000. Quadrant Capital Group LLC also demonstrated its confidence by investing 61.6% more by purchasing additional shares valued at $43,000. Belpointe Asset Management LLC and Ronald Blue Trust Inc., too, secured a new stake in Acadia Healthcare during the fourth quarter ending on December 31st with investments collectively worth around $93,000.
However, it is noteworthy that institutional investors and hedge funds currently own approximately 99.79% of ACHC stock, indicating that individual investors’ contribution to the stock may be relatively low.
These numbers suggest mixed sentiments regarding the future of ACHC stock expected between Q2 2023 and Q1 2025 as reported by Zacks Research analysts’ predictions during May 5th’s research note release.
While these estimations present a concerning picture for individual investors looking to invest in Acadia Healthcare Company Inc., one must consider alternate factors impacting these verdicts while crunching data from various sources before making financial decisions.
In conclusion, Acadia Healthcare’s recent fluctuations may cause an impact on potential earnings amounts; however, there seems to be a bullish feeling from hedge funds and investors and should ideally encourage the average investor to stay optimistic when investing in the market.
